Acyclovir suspension (acyclovir) NDC 17856-2170

NDC codes

FDA NDC Directory

Product NDC (as listed)17856-2170Labeler and product segments. Claims need a package NDC.

Product NDC at billing width17856-2170Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
17856-2170-1	17856217001	72 CUP, UNIT-DOSE in 1 CASE (17856-2170-1) / 5 mL in 1 CUP, UNIT-DOSEMarketed from May 4, 2026
17856-2170-2	17856217002	72 CUP, UNIT-DOSE in 1 CASE (17856-2170-2) / 10 mL in 1 CUP, UNIT-DOSEMarketed from May 4, 2026

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Acyclovir suspension
Generic name (nonproprietary): acyclovir
Active ingredients: Acyclovir — 200 mg/5mL
Dosage form: Suspension
Route: Oral
Labeler: Atlantic Biologicals Corp.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 217393
Marketing start: Mar 9, 2023
Listing expires: Dec 31, 2027
Other FDA classes: DNA Polymerase Inhibitors (Mechanism)Nucleoside Analog (EXT)
Identifiers: Product ID 17856-2170_5105272f-cff9-8898-e063-6394a90aabb5SPL ID 5105272f-cff9-8898-e063-6394a90aabb5SPL set ID 5105272f-cff8-8898-e063-6394a90aabb5RxCUI 307730UNII X4HES1O11F
Pharmacologic class: Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor; Herpes Zoster Virus Nucleoside Analog DNA Polymerase Inhibitor; Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N417856217001 followed by a unit qualifier and the quantity

Package 17856-2170-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective May 4, 2026.

Indications (excerpt from the label)

INDICATIONS AND USAGE Herpes Zoster Infections Acyclovir is indicated for the acute treatment of herpes zoster (shingles). Genital Herpes Acyclovir is indicated for the treatment of initial episodes and the management of recurrent episodes of genital herpes. Chickenpox Acyclovir is indicated for the treatment of chickenpox (varicella).

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 217393

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 217393
Product	Strength	Form · route	Labeler	Product NDC
Acyclovir suspensionacyclovir	Acyclovir 200 mg/5mL	SuspensionOral	Novadoz Pharmaceuticals LLC	72205-170